Iqvia launches new division to support emerging biotech market

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/JK1991)
(Image: Getty/JK1991)

Related tags: Iqvia Biotech, IQVIA, Biotechnology, Biopharmaceutical

To support the emerging biotech and biopharma industry, Iqvia today has announced a new dedicated division: Iqvia Biotech.

According to the company, the new division will design clinical and commercial solutions specifically for early-stage life sciences companies. Supported by more than 1,000 employees, the solutions suite provides simplified operating procedures, specialized teams, and services across drug development and commercialization.

“We designed this comprehensive solutions suite to address what our biotech customers were asking for — transparent and fit-for-purpose clinical processes with dedicated, therapeutically-aligned partners coupled with our unique set of enterprise capabilities,”​ said Iqvia CEO and Chairman Ari Bousbib in a press release.

Main therapy areas of focus for the new division include oncology, central nervous system, dermatology, cardiovascular, and immunology.

Iqvia also recently launched the next generation of its site portal technology to support sharing cross-trial training materials and safety notifications. Two of the top five pharmaceutical companies were involved in the design and testing, and are now using the upgraded platform, according to Iqvia.

Dedicated biotech divisions

The launch of Iqvia Biotech follows the unveiling of Parexel Biotech​ in early January – and a record-breaking 2018 in terms of biotech funding.

However, it is unlikely that this same pace will continue, though some of this is “just a healthy normalization,”Evercore ISI senior managing director and partner, equity research, Ross Muken previously told us​.

David Windley, CFA, CPA, equity analyst, Jefferies LLC, said, “Biotech funding in 2019 is probably going to be flat or maybe down a little bit versus 2018,” ​ though it is doubtful it will have the same negative effect seen in late 2015. Still, it could complicate hiring plans at CROs, but it is unlikely it will have any significant impact on the core business.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars